BCL2 Gene Therapy Vector for Retinal Ganglion Cell Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma primarily focus on lowering intraocular pressure, which slows disease progression but does not directly address the degeneration of retinal ganglion cells, leading to ongoing vision loss, and there is a need for a therapeutic that directly targets these cells to enhance treatment efficacy.
Innovation Solution
The use of vectors comprising a phosphoglycerate kinase promoter operably connected to a polynucleotide encoding an anti-apoptotic BCL2 protein, specifically BCLXL, delivered via adeno-associated virus serotype 2, to promote expression in retinal ganglion cells and prevent apoptosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If IOP-lowering therapy is used to treat glaucoma, then disease progression is slowed, but retinal ganglion cell degeneration continues and vision loss progresses
Solution Approach 1:
The patent introduces BCL2 protein as an intermediary substance that mediates protection between the retinal ganglion cells and apoptotic damage. The viral vector delivers BCL2 gene therapy to the retina, where the BCL2 protein acts as a mediator to block apoptosis pathways and protect neurons from degeneration, thereby addressing the harmful effect that IOP-lowering therapy does not prevent
Solution Approach 2:
The patent applies preliminary protective action by delivering BCL2 gene therapy before or during the early stages of retinal ganglion cell degeneration. By establishing BCL2 expression in advance, the therapy creates a protective mechanism that prevents apoptotic cell death before it occurs, rather than attempting to reverse damage after it has happened
2Stress or pressure
If conventional IOP-lowering treatment is administered, then intraocular pressure is reduced, but direct protection of retinal ganglion cells is not achieved
Solution Approach 1:
The patent introduces BCL2 protein as a molecular intermediary that directly interacts with apoptotic pathways in retinal ganglion cells. This intermediary substance provides cell survival protection by binding to and inhibiting pro-apoptotic proteins, thereby achieving direct cellular protection that IOP-lowering therapy cannot provide
Solution Approach 2:
The patent changes the therapeutic parameter from mechanical/physical intervention (IOP reduction) to molecular/biological intervention (BCL2 protein expression). By altering the mode of action from pressure management to cellular protection mechanisms, the therapy achieves direct protection of retinal ganglion cell survival
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively prevents cell loss in the retinal ganglion cell layer, attenuates axonal degeneration, and protects visual function in glaucoma models by inhibiting BAX recruitment and activation, offering extended protection beyond conventional treatments.
Implementation Method 1
vectors comprising a phosphoglycerate kinase (Pgk) promoter operably connected to a polynucleotide encoding an anti-apoptotic BCL2 protein
Implementation Method 2
delivered via adeno-associated virus serotype 2
Implementation Method 3
prevents apoptosis by inhibiting BAX recruitment and activation
Data Source
AI summary
The present invention provides vectors for delivery of an anti-apoptotic therapy. The vectors include a phosphoglycerate kinase (Pgk) promoter operably connected to a polynucleotide encoding an anti-apoptotic BCL2 protein (e.g., BCLXL). The vectors may be used in methods of treating conditions associated with apoptosis, including glaucoma.